MedPath

A Bioequivalence Study Using Clinical Endpoint for Diclofenac Sodium Gel 1% in Osteoarthritis Knee"

Phase 3
Completed
Conditions
Osteoarthritis, Knee
Interventions
Registration Number
NCT03172780
Lead Sponsor
Mylan Pharmaceuticals Private Limited
Brief Summary

This randomized, double-blind, three-arm, placebo controlled, bioequivalence study with clinical endpoint has been designed to establish clinical equivalence and safety of Mylan's diclofenac gel in the symptomatic treatment of osteoarthritis of knee compared to Voltaren® gel and to establish superiority in efficacy of both compared to a placebo (vehicle) gel.

Male or non-pregnant female aged ≥ 35 years with a clinical diagnosis of osteoarthritis of the knee according to the American College of Rheumatology (ACR) criteria

Total study duration for the clinical part will be around 56 days that includes screening period of 28 days and treatment period of 4 weeks.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1220
Inclusion Criteria
  • Osteoarthritis knee as per American College of Rheumatology (ACR) criteria
  • Evidence of OA with Kellgren-Lawrence grade 1-3 disease.
  • After discontinuing all pain medications, had at least moderate pain on movement (POM) for target knee
  • After discontinuing all pain medications for at least 7 days has a baseline Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC Likert (version 3.1)) pain subscale of ≥ 9 immediately prior to randomization.
  • Able to tolerate rescue medication with acetaminophen
  • Subjects who can read and understand WOMAC pain sub scale
Exclusion Criteria
  • Pregnancy, lactation
  • OA of Kellgren-Lawrence grade 4
  • OA pain in the contralateral knee requiring medication (OTC or prescription)
  • History of OA of either Hip or Hands
  • History of secondary OA (e.g. congenital, traumatic, gouty arthritis), rheumatoid arthritis
  • History of chronic inflammatory disease (e.g., colitis) or fibromyalgia
  • History of Drugs or Alcohol abuse within the previous year
  • Symptomatic peripheral vascular disease of the study leg
  • Any musculoskeletal condition
  • Skin disease at the application site
  • Active asthma requiring periodic treatment with systemic steroids
  • Known history of positive HIV, hepatitis C virus, or HBsAg
  • Uncontrolled hypertension
  • History of myocardial infarction, thrombotic events, stroke etc.
  • Allergy to aspirin, nonsteroidal anti-inflammatory drugs (NSAID) or acetaminophen (paracetamol).

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Diclofenac Sodium GelDiclofenac sodium gel 1%Diclofenac Sodium Gel, 1%
Placebo gelPlacebo gelPlacebo gel
Voltaren® GelVoltaren® Gel (Diclofenac Sodium Topical Gel) 1%Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%
Primary Outcome Measures
NameTimeMethod
Change From Baseline in WOMAC Pain Subscale Score4 weeks

Mean change in the total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain subscale score for the target knee was compared to determine the superiority of the Test Drug and Reference Listed Drug (RLD) over placebo.

Measure Description: Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale score (pain score = min 0 to max 20), was determined by the sum of subject's responses to five questions (S1-S5) using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4). Higher values represent worse outcome.

'How much pain do you have' when 'Walking on a flat surface' (S1), 'Going up or down stairs' (S2), 'at night while in bed' (S3), 'Sitting or lying' (S4), 'Standing upright' (S5)\].

The timepoints considered for the primary outcomes include baseline and week 4.

Mean Change in the Total WOMAC Pain Subscale ScoreFrom baseline to week 4

Mean change in the total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain subscale score for the target knee was compared to determine the clinical equivalence of Test Drug (Diclofenac sodium gel of 1% of Mylan Inc.) with the Reference Listed Drug (RLD) (Voltaren® Gel 1% of Novartis Consumer Health, Inc.) Measure Description: Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale score (pain score = min 0 to max 20), was determined by the sum of subject's responses to five questions (S1-S5) using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4). Higher values represent worse outcome.

'How much pain do you have' when 'Walking on a flat surface' (S1), 'Going up or down stairs' (S2), 'at night while in bed' (S3), 'Sitting or lying' (S4), 'Standing upright' (S5)\].

The timepoints considered for the primary outcomes include baseline and week 4.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (32)

King George Hospital

🇮🇳

Visakhapatnam, Andhra Pradesh, India

Sree Narayana Institute of Medical Science

🇮🇳

Ernakulam, Kerala, India

Mysore Medical College and Research Institute

🇮🇳

Mysore, Karnataka, India

Lokmanya Tilak Municipal Medical College & General Hospital

🇮🇳

Mumbai, Maharashtra, India

Government Medical College and Hospital

🇮🇳

Nagpur, Maharashtra, India

IMS and SUM Hospital

🇮🇳

Bhubaneshwar, Odisha, India

SSG Hospital and Medical College

🇮🇳

Baroda, Gujarat, India

Parul Sevashram Hospital

🇮🇳

Vadodara, Gujarat, India

BJ medical college & Sassoon General Hospital

🇮🇳

Pune, Maharashtra, India

Govt Stanley Medical College & Hospital

🇮🇳

Chennai, Tamil Nadu, India

B.J Medical College & Civil Hospital

🇮🇳

Ahmedabad, Gujarat, India

Yashoda Hospital -Somajiguda

🇮🇳

Somajiguda, Andhra Pradesh, India

Yashoda Hospital - Malakpet

🇮🇳

Hyderabad, Andhra Pradesh, India

Riddhi Medical Nursing Home

🇮🇳

Ahmedabad, Gujarat, India

Rathi Hospital

🇮🇳

Ahmedabad, Gujarat, India

Omega Hospital

🇮🇳

Mangalore, Karnataka, India

M.V. Hospital & Research Centre

🇮🇳

Lucknow, Uttar Pradesh, India

Ajanta Research Centre

🇮🇳

Lucknow, Uttar Pradesh, India

OM surgical Centre and Maternity Home

🇮🇳

Varanasi, Uttar Pradesh, India

Institute of Post Graduate Medical Education and Research (IPGMER), Department of Orthopaedics

🇮🇳

Kolkata, West Bengal, India

Yashoda Hospital -Secunderabad

🇮🇳

Secunderabad, Andhra Pradesh, India

Medistar Multispeciality Hospital

🇮🇳

Himmatnagar, Gujarat, India

Sanjivani Superspeciality Hospital Pvt. Ltd

🇮🇳

Ahmedabad, Gujarat, India

GMERS Medical College & Civil Hospital

🇮🇳

Ahmedabad, Gujarat, India

Shree Giriraj Multispeciality Hospital

🇮🇳

Rajkot, Gujarat, India

Sir J. J. Group of Hospital and Grant Government Hospital

🇮🇳

Mumbai, Maharashtra, India

Institute of Medical sciences and Lata Mangeshkar

🇮🇳

Nagpur, Maharashtra, India

Supe Heart and Diabetes Hospital & Research Centre

🇮🇳

Nashik, Maharashtra, India

BhaktiVedanta Hospital and Research Institute

🇮🇳

Thane, Maharashtra, India

Anand Multispeciality Hospital

🇮🇳

Vadodara, Gujarat, India

Jasleen Hospital

🇮🇳

Nagpur, Maharashtra, India

Sancheti Institute for Orthopedics & Rehabilitation

🇮🇳

Pune, Maharashtra, India

© Copyright 2025. All Rights Reserved by MedPath